TABLE I.
Baseline characteristics of subjects with CD4+ lymphocyte gene expression profiles in CAMP
| Variable | White (n = 205) | Black (n = 49) | P value |
|---|---|---|---|
| Male gender (n, %) | 123 (60%) | 28 (57%) | 0.74 |
| Age (years)a | 20.4 (2.2) | 20.6 (1.8) | 0.64 |
| Height (cm)a | 171.9 (9.1) | 170.5 (9.2) | 0.30 |
| Self-reported current smoking history (n, %) | 26 (13%) | 3 (6%) | 0.31 |
| Pre-bronchodilator FEV1 (% predicted) | 97.3 (12.2) | 94.4 (12.7) | 0.16 |
| Pre-bronchodilator FVC (% predicted) | 109.2 (10.8) | 106.9 (13.1) | 0.27 |
| Pre-bronchodilator FEV1/FVC | 77.4 (7.6) | 77.8 (8.4) | 0.74 |
| Inhaled corticosteroid use (n, %) | 49 (23%) | 11 (22%) | 0.85 |
| Long-acting bronchodilator use (n, %) | 27 (13%) | 6 (12%) | 0.83 |
| Total serum IgE level (IU/ml)b | 312.9 (134.7–781.4) | 581.7 (141–438.5) | 0.02 |
| Eosinophil count (cells/ml3)b | 212 (141–360.4) | 249 (141–438.5) | 0.11 |
FEV1, forced expiratory volume in one second; CAMP, Childhood Asthma Management Program; IgE, immunoglobulin E.
a
Mean (standard deviation).
b
Median (interquartile range).